Journal articleHuman
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
Science translational medicine, 2024 Dec 18. Sloop KW, Cox AL, Wainscott DB and 20 others.
Study type
Journal article
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Science translational medicine
Published
2024 Dec 18
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
Glucagon-Like Peptide-1 ReceptorAnimalsHumansMiceRatsMaleSignal TransductionHEK293 CellsGlucose Tolerance TestMice, Inbred C57BLOxadiazolesFluorine Compounds
Other papers on Orforglipron
Randomized controlled trial · 2026
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
Randomized controlled trial · 2026Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
Randomized controlled trial · 2026Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial
Randomized controlled trial · 2025Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Randomized controlled trial · 2025Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Randomized controlled trial · 2023Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page